Finch Therapeutics Group, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Matthew Blischak
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Inner Belt Road Somerville MA United States of America 02143
- IPO Date
- Mar 19, 2021
- CIK
- 0001733257
- Website
- finchtherapeutics.com
- Similar Companies
- Business
- Finch Therapeutics Group, Inc. (FNCH) is a clinical-stage microbiome therapeutics company that develops orally administered biological drugs derived from human microbiota transplantation studies to address dysbiosis-related diseases; its pipeline includes CP101, a late-stage investigational candidate for recurrent Clostridioides difficile infection with Breakthrough Therapy and Fast Track FDA designations, FIN-211 targeting gastrointestinal and behavioral symptoms in children with autism spectrum disorder, FIN-524 for ulcerative colitis, and FIN-525 for Crohn's disease. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates primarily in the United States, leveraging its Human-First Discovery platform for reverse translation from clinical data and maintaining license agreements with Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, OpenBiome, Arizona State University, and the University of Minnesota. In recent strategic shifts, Finch discontinued its Phase 3 trial of CP101 in January 2023 to focus on monetizing its intellectual property estate of over 70 patents, restructured operations with significant workforce reductions to extend its cash runway into 2025, announced the resignation of its Chief Financial Officer in January 2025, implemented a reverse stock split, and delisted from Nasdaq in October 2024 while deregistering with the SEC to cut compliance costs, with shares continuing on OTC markets amid ongoing litigation against Ferring Pharmaceuticals for patent infringement.
Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.7% – Here’s What Happened
Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)
Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)
Financial Survey: ZIVO Bioscience (NASDAQ:ZIVO) versus Finch Therapeutics Group (NASDAQ:FNCH)
Arquitos Capital's Largest Holdings For Q1 2025
Finch Announces Delisting from Nasdaq and SEC Deregistration
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
Why Finch Therapeutics Stock Is Skyrocketing Today
Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
Best Penny Stocks to Buy Today? 3 to Watch on April 29th
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes